Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: SPAIN - REVIEW
The health system is decentralised, which means that health provision varies from region to region. Public health expenditure represents about three-quarters of total health expenditure but private health expenditure, which mainly comprises out-of-pocket expenditure and private health insurance, has increased at a higher rate in recent years. However, this growth is expected to slow down due to the economic downturn. In terms of health infrastructure, Spain is well served to provide hospital and outpatient care. The health workforce is strong, although there is some concern that there are not enough physicians in the SNS, particularly in the paediatrics, radiology, anaesthesiology, family medicine and pathological anatomy specialties.
In August 2011, Spain passed a new Royal Decree Law that included a number of new austerity measures to help reduce the country's budget deficit. Some measures affected the health sector, in order to better sustain the SNS and improve health quality, equity and cohesion. With the new austerity measures, the government aims to obtain considerable savings in SNS pharmaceutical expenditure and patient co-payment fees. These savings are additional to those resulting from the implementation of Royal Decree Laws No. 4/2010 and No. 8/2010; these two Royal Decree Laws resulted in a fall of 2.4% in SNS pharmaceutical expenditure in 2010.
The Spanish pharmaceutical market ranks fifth highest in Western Europe. However, it ranks much lower in per capita terms. The economic slowdown has affected the pharmaceutical industry in recent years. Espicom projects a low CAGR in euro terms and in US dollar terms between 2011 and 2016; the CAGR in US dollar terms is lower than previously projected due to a weaker projected exchange of the euro against the US dollar. The pharmacy sector is expected to increase at a slower rate than the hospital sector, but cost-containment policies will affect both sectors. Almirall and Esteve are the best positioned local companies.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
